Ascendis Pharma A/S (NASDAQ:ASND) Posts Quarterly Earnings Results, Misses Expectations By $0.68 EPS

Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Thursday. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68), FiscalAI reports. The business had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 246.61%.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• Q2 revenue more than doubled year over year to €339 million, including €315 million of product revenue and a €17 million TransCon CNP milestone. Management also reported €207 million of net profit and €812 million in cash and cash equivalents.
• YORVIPATH demand remained robust, with approximately 1,000 new U.S. patient enrollments per quarter and availability commercially or through named-patient programs in more than 35 countries. Long-term data showed sustained efficacy, quality-of-life improvements, and patient retention of up to 95% after five years.
• YUVIWEL uptake is accelerating, with more than 220 U.S. enrollments and over 65% approved for reimbursement by the end of July. Management believes the product is expanding the achondroplasia treatment market and could become the leading therapy, supported by planned global launches and a phase III combination trial with TransCon growth hormone.
• Management reiterated confidence in its long-term growth targets, including more than €500 million of operating cash flow in 2026 and €5 billion of revenue by 2030, while expecting increased operating leverage as launches scale.
• YUVIWEL remains subject to an ongoing U.S. intellectual-property dispute with BioMarin, with an initial ITC opinion expected in August, a broader ITC decision in December, and a potential presidential review thereafter. Management expects no material impact, but the legal process remains a source of uncertainty.

Ascendis Pharma A/S Trading Up 0.9%

ASND opened at $248.50 on Friday. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The firm has a market cap of $15.50 billion, a PE ratio of 19.28 and a beta of 0.39. The firm’s fifty day moving average is $249.60 and its two-hundred day moving average is $237.24.

Insider Transactions at Ascendis Pharma A/S

In related news, Director Jean Jacques Bienaime bought 400 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were purchased at an average cost of $237.80 per share, for a total transaction of $95,120.00. Following the acquisition, the director owned 400 shares of the company’s stock, valued at approximately $95,120. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisory Services Network LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter worth $26,000. Arax Advisory Partners raised its stake in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 104 shares during the period. Global Retirement Partners LLC lifted its holdings in shares of Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares in the last quarter. GW&K Investment Management LLC boosted its position in shares of Ascendis Pharma A/S by 75.2% during the fourth quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock worth $48,000 after buying an additional 97 shares during the period. Finally, Quadrant Capital Group LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth about $74,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company lowered their price objective on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Oppenheimer reissued an “outperform” rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. Barclays reduced their target price on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a research note on Friday. Weiss Ratings raised shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Finally, Evercore reaffirmed an “outperform” rating and set a $329.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Buy” and an average target price of $299.24.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.